Summary
GlobalData, the industry analysis specialist's new report, "Insomnia-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global insomnia market. The report identifies the key trends shaping and driving the global insomnia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global insomnia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes
-Annualized global insomnia market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include GABA receptor targetters, serotonin receptor targetters, melatonin receptor agonists, histamine receptor antagonists, orexin receptor antagonists.
-Analysis of the current and future market competition in the global insomnia market. Key market players covered are Sanofi Aventis, Somaxon Pharmaceuticals, Vanda Pharmaceuticals Inc., Merck and GlaxoSmithKline.
-Insightful review of the key industry drivers, restraints and challenges.  Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with insomnia.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global insomnia market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global insomnia market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective   counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global insomnia market landscape?-Identify,   understand and capitalize.

Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Insomnia Market: Market Characterization 6
2.1 Overview 6
2.2 Insomnia Market Size 6
2.3 Insomnia Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Insomnia Market 7
2.4.1 Drivers for the Insomnia Market 7
2.4.2 Barriers for the Insomnia Market 7
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Insomnia Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Sales for Major Insomnia Products 11
3.4 Product Profile for the Major Marketed Products in the Insomnia Market 11
3.4.1 Ambien CR (zolpidem tartrate extended-release) 11
3.4.2 Lunesta 12
3.4.3 Rozerem 13
3.5 Other Marketed Products for the Insomnia Market 14
3.5.1 Zolpimist (zolpidem oral spray) 14
3.5.2 Edluar (zolpidem sublingual tablets) 15
3.5.3 Circadin (prolonged release melatonin) 15
3.6 Key Takeaway 17
4 Insomnia Market: Pipeline Assessment 18
4.1 Overview 18
4.2 Strategic Pipeline Assessment 18
4.2.1 Technology Trends Analytic Framework 18 
4.3 Insomnia Therapeutics-Promising Drugs under Clinical Development 20
4.4 Molecule Profile for Promising Drugs under Clinical Development 21
4.4.1 Ciltyri (eplivanserin) 21
4.4.2 Almorexant 21
4.4.3 Silenor (doxepin hydrochloride) 22
4.4.4 Tasimelteon (VEC-162) 22
4.4.5 Esmirtazapine (ORG 50081) 23
4.4.6 Indiplon 24
4.5 Insomnia Therapeutics Market-Clinical Pipeline by Mechanism of Action 24
4.6 Insomnia Pipeline-Pipeline by Clinical Phases of Development 25
4.6.1 Insomnia Therapeutics-Regulatory and Phase III Clinical Pipeline 25
4.6.2 Insomnia Therapeutics-Phase II Clinical Pipeline 26
4.6.3 Insomnia Therapeutics-Phase I Clinical Pipeline 27
4.6.4 Insomnia Therapeutics-Preclinical Pipeline 27
4.6.5 Insomnia Therapeutics-Discovery Pipeline 27
4.7 Discontinued/Suspended Drugs for Insomnia 27
4.8 Key Takeaway 29
5 Insomnia Market: Implications for Future Market Competition 30
6 Insomnia Market: Future Players in Insomnia Market 31
6.1 Introduction 31
6.2 GlaxoSmithKline 32
6.2.1 Overview 32
6.2.2 CNS Portfolio 32
6.2.3 Insomnia Product Portfolio 34
6.3 Sanofi Aventis 35
6.3.1 Overview 35
6.3.2 CNS Portfolio 35
6.3.3 Insomnia Product Portfolio 35
6.4 Somaxon Pharmaceuticals 36
6.4.1 Overview 36
6.4.2 CNS Portfolio 36
6.4.3 Insomnia Product Portfolio 36
6.5 Vanda Pharmaceuticals Inc. 37
6.5.1 Overview 37
6.5.2 CNS Portfolio 37
6.5.3 Insomnia Product Portfolio 37
6.6 Merck 38
6.6.1 Overview 38
6.6.2 CNS Portfolio 38
6.6.3 Insomnia Product Portfolio 38
7 Insomnia Market: Appendix 40
7.1 Definitions 40
7.2 Acronyms 40
7.3 Research Methodology 41
7.3.1 Coverage 41
7.3.2 Secondary Research 42
7.3.3 Forecasting 42
7.3.4 Primary Research 44
7.3.5 Expert Panel Validation 45
7.4 Contact Us 45
7.5 Disclaimer 45
7.6 Sources 45

List of Tables
1.1 List of Tables
Table 1: Global Insomnia Therapeutics Market, Revenue Forecasts, 2000-2008 7
Table 2: Global Insomnia Therapeutics Market, Revenue Forecasts, 2009-2015 7
Table 3: Major Marketed Products Comparison in the Insomnia Market, 2009 17
Table 4: Insomnia Therapeutics-Most Promising Drugs under Clinical Development, 2009 20
Table 5: Insomnia Therapeutics-Regulatory Filing and Phase III Clinical Pipeline, 2009 25
Table 6: Insomnia Therapeutics-Phase II Clinical Pipeline, 2009 26
Table 7: Insomnia Therapeutics-Phase I Clinical Pipeline, 2009 27
Table 8: Insomnia Therapeutics-Preclinical Pipeline, 2009 27
Table 9: Insomnia Therapeutics-Discovery Pipeline, 2009 27
Table 10: List of Discontinued Drugs for Insomnia, 2009 27
Table 11: GlaxoSmithKline-CNS Marketed Products, 2009 32
Table 12: GlaxoSmithKline-CNS Pipeline Products, 2009 33
Table 13: Sanofi Aventis-CNS Marketed Products, 2009 35
Table 14: Sanofi Aventis-CNS Pipeline Products, 2009 35
Table 15: Somaxon Pharmaceuticals-CNS Pipeline Products, 2009 36
Table 16: Vanda Pharmaceuticals Inc.-CNS Pipeline Products, 2009 37
Table 17: Merck-CNS Marketed Products, 2009 38
Table 18: Merck -CNS Pipeline Products, 2009 38

List of Figures
1.2 List of Figures
Figure 1: Global Insomnia Market Forecast 2000-2015 6
Figure 2: Opportunity and Unmet Need in the Insomnia Market, 2009 9
Figure 3: Strategic Competitor Assessment of the Major Marketed Products for Insomnia, 2009 10
Figure 4: Global Sales of Top Insomnia Products, 2009 11
Figure 5: Technology Trends Analytic Framework of the Insomnia Pipeline, 2009 18
Figure 6: Technology Trends Analytic Framework of the Insomnia Pipeline-Description, 2009 19
Figure 7: Insomnia Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2009 25
Figure 8: Insomnia Pipeline by Phase of Clinical Development, 2009 25
Figure 9: Implications for Future Market Competition in the Insomnia Market, 2009 30
Figure 10: Insomnia Therapeutics Market-Clinical Pipeline by Company, 2009 31
Figure 11: GlobalData Methodology 41
Figure 12: GlobalData  Market Forecasting Model 44